Hepatitis B virus (HBV) reactivation in the setting of immunosuppressive therapy is an
increasingly recognized and preventable cause of elevated liver enzymes and clinical …

Background: The optimal management of HBsAg-negative, anti-HBc-positive patients who
receive immunosuppression remains unclarified. We systematically reviewed the available …

Our understanding of hepatitis B virus (HBV) reactivation during immunosuppresive therapy
has increased remarkably during recent years. HBV reactivation in hepatitis B surface …

The proportion of hepatitis B virus (HBV) previously exposed patients who receive
immunosuppressive treatment is usually very small. However, if these individuals are …

INTRODUCTION—The natural course of hepatitis B virus (HBV) infection is determined
through the interplay between viral replication and the host's immune response. HBV …

Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving
immunosuppressive therapy has been a growing concern, particularly in the era of …

Abstract Hepatitis B (HBV) reactivation (HBVr) is a potentially fatal complication in patients
with past HBV exposure receiving immunosuppressive therapy. HBVr can occur in patients …

Background Reactivation of hepatitis B virus (HBV) replication in patients with chronic or
past HBV infection receiving immunosuppressive therapy (IST) can be prevented through …

Patients with current or past hepatitis B virus (HBV) infection are at risk of viral reactivation if
they receive immune-modulating treatment or chemotherapy. This can range from …

Background The role of antiviral prophylaxis before chemotherapy or immunosuppressive
therapy to prevent hepatitis B virus (HBV) reactivation in patients with resolved HBV infection …